US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

Ropivacaine HCl 0.25% in 0.9% Sodium Chloride

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-185-75 D-0203-2017
Class II · Moderate risk Terminated

Rocuronium Bromide 50 mg/5 mL Injection Solution

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-064-15 D-0202-2017
Class II · Moderate risk Terminated

Morphine Sulfate 1 mg/mL in 0.9% Sodium Chloride

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-160-75 D-0199-2017
Class II · Moderate risk Terminated

Lidocaine HCl 1%

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company D-0197-2017
Class II · Moderate risk Terminated

Heparin Sodium 5

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-097-24 D-0193-2017
Class II · Moderate risk Terminated

Heparin Sodium

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-148-16 D-0192-2017
Class II · Moderate risk Terminated

Glycopyrrolate 1 mg/5 mL

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-028-15 D-0191-2017
Class II · Moderate risk Terminated

Fentanyl Citrate 2

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-024-61 D-0189-2017
Class II · Moderate risk Terminated

Fentanyl Citrate 1

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-024-35 D-0188-2017
Class II · Moderate risk Terminated

Calcium Chloride

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company D-0187-2017
Class II · Moderate risk Terminated

Calcium Chloride

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-102-09 D-0186-2017
Class II · Moderate risk Terminated

Phenylephrine HCl 1 mg/10 mL

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-171-12 D-0185-2017
Class II · Moderate risk Terminated

Calcium Chloride 1 g/50 mL* Added to 5% Dextrose

Reason Lack of Assurance of Sterility - the firm is recalling select sterile drug products.

Cantrell Drug Company NDC 52533-175-37 D-0184-2017
Class III · Low risk Terminated

Sodium Ferric Gluconate Complex in Sucrose Injection

Reason Subpotent Drug: Product has an an out of specification in iron assay analysis found during 18 month stability testing.

West-Ward Pharmaceuticals Corp. NDC 0143-9570-10 D-0172-2017
Class II · Moderate risk Terminated

Desoximetasone Ointment USP

Reason Failed Stability Specifications; out-of specification value for homogeneity / phase separation.

Akorn Inc NDC 61748-206-15 D-0152-2017
Class I · High risk Terminated

Ultimate Body Tox PRO capsules

Reason Marketed Without An Approved NDA/ANDA: The product contains undeclared sibutramine. The presence of sibutramine, a previously approved controlled substance that was removed from the U.S. market in October 2010 for safety reasons, in this tainted product renders it an unapproved drug for which safety and efficacy have not been established and therefore subject to recall.

Ultimate Body Tox D-0210-2017
Class II · Moderate risk Terminated

Lactulose Solution

Reason Microbial Contamination of Non-Sterile Products: bulk solution tested positive for the presence of the bacteria, Burkholderia cepacia.

VistaPharm, Inc. NDC 66689-039-01 D-0146-2017
Class II · Moderate risk Terminated

L-Cysteine Hydrochloride Injection

Reason Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.

Sandoz Inc NDC 66758-005-01 D-0141-2017